Federal regulation of tissues and organs has proceeded slowly, with main emphasis on safety of the procured material. More recently with the development of somatic cell therapies, the Food and Drug Administration has issued some guidance documents that establish that some classes of cells that are manufactured will be subject to not only safety but efficacy requirements. Cell transplantation presents several aspects that are similar to somatic cell therapies, and the purpose of this presentation is to explore those relationships.
Food and Drug Administration, DHHS.Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products; Notice.Federal Register, vol. 58, no. 197. Thursday, October 14, 1993.
2.
Food and Drug Administration, DHHS. 21 CFR Parts 16, et al. Human Tissue Intended for Transplantation; Interim Rule.Federal Register, vol. 58, no. 238. Tuesday, December 14, 1993.
3.
KesslerD.A.; SiegelJ.P.; NoguchiP.D.; ZoonK.C.; FeidenK.L.; WoodcockJ.W.FDA regulation of somatic-cell therapy and gene therapy.N. Engl. J. Med.329: 1169–1173; 1993.
4.
PittmanM.The regulation of biologic products, 1902-1972. In: GreenwaldH.R.; HardenV.A. eds. National Institute of Allergy and Infectious Disease: Intramural contributions, 1887-1987.Washington, D.C.: Department of Health and Human Services;1987: 61–70.
